Reducing margins for abdominopelvic tumors in dogs: impact on dose‐coverage and normal tissue complication probability by Meier, Valeria Sabina et al.








Reducing margins for abdominopelvic tumors in dogs: impact on
dose‐coverage and normal tissue complication probability
Meier, Valeria ; Staudinger, Chris ; Radonic, Stephan ; Besserer, Jürgen ; Schneider, Uwe ; Walsh,
Linda ; Rohrer Bley, Carla
Abstract: Image‐guided, intensity modulated radiation therapy (IG‐IMRT) reduces dose to pelvic organs
at risk without losing dose coverage to the planning target volume (PTV) and might permit margin
reductions potentially resulting in lower toxicity. Appropriate PTV margins have not been established
for IG‐IMRT in abdominopelvic tumours in dogs, and herein we explore if our usual PTV 5 mm margin can
be reduced further. Datasets from dogs that underwent IG‐IMRT for non‐genitourinary abdominopelvic
neoplasia with 5 mm‐PTV expansion were included in this retrospective virtual study. The clinical
target volumes and organs at risk (OAR) colon, rectum, spinal cord were adapted to each co‐registered
cone‐beam computed tomography (CBCT) used for positioning. New treatment plans were generated and
smaller PTV margins of 3 mm and 4 mm evaluated with respect to adequate dose coverage and normal
tissue complication probability (NTCP) of OAR. Ten dogs with a total of 70 CBCTs were included.
Doses to the OAR of each CBCT deviated mildly from the originally planned doses. In some plans,
insufficient build‐up of the high dose‐area at the body surface was found due to inadequate or missing
bolus placement. Overall, the margin reduction to 4 mm or 3 mm did not impair dose coverage and led to
significantly lower NTCP in all OAR except for spinal cord delayed myelopathy. However, overall NTCP
for spinal cord was very low (<4%). PTV‐margins depend on patient immobilization and treatment
technique and accuracy. IG‐IMRT allows treatment with very small margins in the abdominopelvic
region, ensuring appropriate target dose coverage, while minimizing NTCP.
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Abstract
Image-guided, intensity modulated radiation therapy (IG-IMRT) reduces dose to pel-
vic organs at risk without losing dose coverage to the planning target volume (PTV)
and might permit margin reductions potentially resulting in lower toxicity. Appropri-
ate PTV margins have not been established for IG-IMRT in abdominopelvic tumours
in dogs, and herein we explore if our usual PTV 5 mm margin can be reduced further.
Datasets from dogs that underwent IG-IMRT for non-genitourinary abdominopelvic
neoplasia with 5 mm-PTV expansion were included in this retrospective virtual study.
The clinical target volumes and organs at risk (OAR) colon, rectum, spinal cord were
adapted to each co-registered cone-beam computed tomography (CBCT) used for
positioning. New treatment plans were generated and smaller PTV margins of 3 mm
and 4 mm evaluated with respect to adequate dose coverage and normal tissue com-
plication probability (NTCP) of OAR. Ten dogs with a total of 70 CBCTs were
included. Doses to the OAR of each CBCT deviated mildly from the originally planned
doses. In some plans, insufficient build-up of the high dose-area at the body surface
was found due to inadequate or missing bolus placement. Overall, the margin reduc-
tion to 4 mm or 3 mm did not impair dose coverage and led to significantly lower
NTCP in all OAR except for spinal cord delayed myelopathy. However, overall NTCP
for spinal cord was very low (<4%). PTV-margins depend on patient immobilization
and treatment technique and accuracy. IG-IMRT allows treatment with very small
margins in the abdominopelvic region, ensuring appropriate target dose coverage,
while minimizing NTCP.
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1 | INTRODUCTION
Compared to three-dimensional conformal radiation therapy (3D-
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to pelvic organs at risk (OAR) without losing dose coverage to the
planning target volume (PTV).1-3 The precision of IMRT additionally
increases with image guidance: Using on-board imaging devices
(OBI), high quality orthogonal kV-images or images acquired in an
arc rotation (cone-beam computed tomography, CBCT) provide
excellent 3D anatomical information and bone- and soft-tissue visi-
bility.4-7 Such images of the patient's set-up are taken at the begin-
ning of each treatment session and aligned to reference images from
the treatment plan. Then, patient's position can immediately be
corrected if required. The position is typically adjusted with a couch
positional shift, and possible in four degrees of freedom - longitudi-
nal, vertical, horizontal, rotational (yaw) - unless a 6D robotic couch
is available allowing for additional pitch and roll corrections.8 The
consequential increase in precision often permits PTV reduction,
which could result in lower toxicity and a shift in therapeutic
ratio.9,10 Appropriate PTV margins have not yet been established for
IG-IMRT treatment of tumours in the dog's abdominopelvic region
and herein we explore if our usual 5 mm margin can be reduced
further.
In contrast to PTV margins, organ (at risk) movement has
been quantified for the dog's abdominopelvic region with CBCT
for image-guided IMRT (IG-IMRT). The extent of displacement is
known for the canine bladder in treating urinary bladder
cancer,11 for prostate and urethra intrafraction motion,12 as well
as for interfraction ureteral movement.13 Earlier, we have com-
puted a PTV expansion margin for dogs with large
abdominopelvic tumours treated with simple 3D-CRT or IMRT,
without image guidance. We extracted daily treatment position
correction data from IG-IMRT treatments and derived a margin
according to one of van Herk et al.'s formula: 2.5Σ + 0.7σ.14 The
resulting clinical target volume (CTV) to PTV expansion margin
was 7x7x18mm (lateral-vertical-longitudinal). This anisotropic
margin can be applied where a rigid, well-reproducible positioning
device is used without imaging position verification.15 For IG-
IMRT treatments, however, this margin can most likely be
smaller. For genitourinary and anal sac tumours a 5 mm PTV mar-
gin has been used, but not further tested.15,16The purpose for
this study was 2fold. Firstly, we wanted to investigate if our cur-
rently used 5 mm PTV margin provides appropriate dose cover-
age to the CTV for IG-IMRT treatment of tumours in dog's
abdominopelvic area. A series of pretreatment CBCTs from dogs
affected by such tumours were used to investigate the PTV mar-
gin, deriving the delivered dose to the effectively treated CTV
positions. The aim was to investigate whether or not the CTV-
PTV expansion of 5 mm could be reduced while still maintaining
coverage of the CTV in the imaging series of each patient. Sec-
ondly, the theoretical clinical impact on normal tissue complica-
tion probability (NTCP) of the initially planned and effectively
delivered doses was calculated for the treatment datasets of for-
merly treated dogs. These NTCPs calculated for 5 mm PTV were
then compared to NTCPs of virtual plans derived for possible
smaller margins to investigate a relative change in possible
toxicity.
2 | METHODS
2.1 | Patient and tumour characteristics
We included datasets from dogs undergoing radiation therapy (RT) for
non-genitourinary neoplasia in the abdominopelvic region at the Divi-
sion of Radiation Oncology, Vetsuisse Faculty, University of Zurich,
Switzerland in this retrospective study. For treatment planning, a pre-
and post-contrast standard computed tomography (CT) scan of the
tumour was performed with a 16 MDCT unit (Brilliance CT 16-slice,
Philips Health Care Ltd, Best, Netherlands) as previously described.17
Patients were placed under general anaesthesia and immobilized in
sternal recumbency with outstretched hind limbs in an individually
shaped vacuum cushion (BlueBag BodyFix, Elekta AB). A tissue-equiv-
alent bolus (Superflab) was placed in a non-standardized manner, usu-
ally over scars in the perianal area. Further information retrieved from
the records included signalment (age, sex and breed), type, size and
location of the primary tumour and metastatic locoregional lymph
nodes.
2.2 | Contouring of organs at risk and target
volumes
Contouring and computer-based treatment planning was performed
with the external beam planning system (Eclipse Planning system, ver-
sion 15.1 Varian Oncology Systems, Palo Alto, California), using Aniso-
tropic Analytical Algorithm (AAA), version 15.1.51, with heterogeneity
correction. Dose calculation was performed on the pre-contrast CT
images. As previously described for this region, contouring of OAR as
well as tumour-related volumes was performed on co-registered post-
contrast CT images in order to increase the accuracy of contouring.18
The body contour and bones were automatically segmented. OAR
contouring included rectum (from the anus until the start of the
colon), colon (from the pelvic inlet, the cranial border of the pelvic
symphysis until transition into the small intestines or alternatively to
the most cranial CT image), spinal cord (cranially from the start of CT
dataset to the caudal end of L7), and cauda equina (the intraspinal part
of all cauda equina nerves contributing to the lumbosacral plexus was
contoured: from the caudal end of L7 to the caudal end of the
sacrum). We contoured tubular structures (rectum and colon) as the
volume within the outer wall contour, including the contents.
Tumour-related volumes were defined as follows: gross tumour vol-
ume (GTV), the visible primary tumour as seen on co-registered
contrast-enhanced CT images, GTV lymph node including metastatic
lymph nodes, clinical target volume (CTV), microscopic disease sur-
rounding the primary tumour (with a 1 cm GTV to CTV expansion
margin) and (non-macroscopically involved) locoregional lymph nodes
and PTV, accounting for systematic and random uncertainties. The
CTV-PTV isotropic expansion margin was 5 mm, as described above,
cropped 1 mm inside the body outline. The targets of the reference
dataset used for treatment planning were labelled with the suf-
fix “_0”.
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2.3 | Matching procedure and image selection
For each patient, several kilovolt (kV)-CBCT were acquired as part of
routine practice, at the radiation oncologist's discretion. CBCT settings
used were 125 kV (x-ray tube voltage), 80 mA (x-ray tube current),
674 mAs (exposure), 16 cm scan length and half fan mode. A full 360
acquisition was used at 180/min. The maximum diameter for recon-
struction was 450 mm; 512x512 pixels and a resolution of 0.88 mm. All
CBCT images were automatically imported into the Eclipse treatment
planning system at their initial setup position, with 2 mm slice spacing.
For treatment, the CBCT images were manually matched to the refer-
ence planning CT by an experienced radiation therapy radiographer,
using soft tissue window level and using the GTV_0/ CTV_0 structures
to ensure optimal match. Upon satisfactory match, the isocenter shifts
were applied by table movement (four dimensions) and stored in the
system. No specific measures were taken to ensure bladder or bowel
emptying before treatment, but all patients were treated in the morn-
ings, after their first walk for urination and defecation.
2.4 | Generating the sum of treated CTVs
and OAR
CTV_0 was copied from the initial treatment plan, the reference
dataset, to each co-registered CBCT. To reflect the daily actual situation
and influence of normal organ filling, also the organs at risk were copied
from the original reference dataset. Both the (copied, that is, new) CTV
and organs at risk were adapted manually on each CBCT by a single
investigator (CS). The adapted CTV and OAR structures (labelled with
the suffixes “_CBCT_1”, “_CBCT_2”, etc. for each CBCT) added to the
original reference dataset. The sum of the treated CVTs was created
with the boolean operator tool, resulting in the structure “CTVbool”.
2.5 | Treatment planning and delivery
Treatment plans were calculated as deliverable by the investigator's
linear accelerator, with a 6 MV linear accelerator (Clinac iX, Varian,
Palo Alto, California). Coplanar photon treatment planning was per-
formed with 5 to 7 fields and additional contouring helper structures
to ensure optimal dose homogeneity, target coverage and minimal
dose to OAR. Dose was optimized with IMRT using a dynamic
120 multi-leaf collimator. Recommendations for specification of dose
were adhered to as proposed by the International Commission on
Radiation Units and Measurements (ICRU) report 83 and as rec-
ommended for veterinary medicine.9,19 The dose was normalized
adhering to the guidelines: the PTV Dnear-min (the minimal dose-
coverage of D98%) was required with 95% of total prescribed dose
(≥98% of the PTV was covered by the 95% isodose line) and D50%
(median dose) as the value of dose prescription. A moderately
hypofractionated dose of 12x3.8Gy was prescribed in this definitive-
intent approach.18 Hence, we set D98% (Dnear-min) to ≥43.32 Gy, D2%
(Dnear-max) to ≤48.79Gy and D50% to 45.6 Gy.
2.6 | Margin reduction and evaluation procedure
An optimal PTV-extension margin was defined for margins as fol-
lows. On average at least 95% of the prescribed dose is delivered to
99% of the CTV.20 While the original, effectively treated plan was
used for PTV5mm (Plan5mm), we generated new plans each, for the
reduced PTVs (4 mm: Plan4mm and 3 mm: Plan3mm): the original plan
was copied and the new target (PTV) was assigned. Using at least
the prior described constraints, the plans were re-optimized and
then re-calculated. The new plans were required to fulfil the pre-
scription criteria as above, with OAR-doses kept as low as possible
through optimization.
2.7 | NTCP calculations for the planned dataset vs
the delivered treatment
For the fraction to fraction NTCP calculations, the effective dose
applied to the OAR was extracted from each contoured CBCT. In-
house analysis codes were used to calculate the NTCP from the dif-
ferential dose-volume histograms (DVH). The NTCPs were then
compared to the dose delivered to the OAR during the fractions
over the course of treatment, as previously described (NTCPplanned;
NTCPdelivered).
18 NTCP was also calculated for the OAR in the subse-
quent plans with PTV4mm and PTV3mm (where the “delivered”
doses were only virtually delivered). The parameter sets were
retrieved from human data and computations performed as previ-
ously published.18
2.8 | Statistical analysis
Data was coded in Excel and analysed with a commercial statistical
software package (IBM SPSS Statistics, Version 25 (IBM Corp.,
Armonk, New York). Shapiro-Wilk testing was carried out to assess nor-
mality. D98%/D50%/D2% dose distributions were assessed graphically with
box-plots and Wilcoxon test was used for paired observations (testing
the differences in doses between the plans). Wilcoxon test was further
used for paired observations (testing the differences in NTCPplanned vs
NTCPdelivered) and to compare organ dose parameters (NTCPs) derived
from the DVHs between the three individual two level comparisons (ie,
3 mm vs 4 mm, 3 mm vs 5 mm, 4 mm vs 5 mm). For the comparison of
the organ at risk NTCPs under the different PTV margins, Friedman's test
(non-parametric, for multiple comparison) was carried out. Differences
were considered significant at P values <.05.
3 | RESULTS
3.1 | Patient population
Ten dogs (two neutered males, two intact males, six spayed
females) were included into this study. The mean age at diagnosis
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was 9.6 ± 2.9 years (range 6.2-12.8 years), and the mean body
weight was 20.6 ± 8.0 kg (range 12.5-40.7 kg). Four dogs were of
mixed breed, there were two Border Collies and one of each of
the following pure breeds: Golden Retriever, Cocker Spaniel, Field
Spaniel and Cavalier King Charles Spaniel. Nine dogs were treated
for lymph node-metastatic anal gland adenocarcinoma (macroscopic
disease or microscopic primary and macroscopic lymph nodes) and one
dog had a pelvic histiocytic sarcoma with locoregional lymph node
involvement.
3.2 | Planned and delivered doses
A mean of 7 (± 3.4) CBCTs were performed (range 3-12) (median 6)
per dog. OAR (rectum, colon, spinal cord, and cauda equina) were
adapted manually in all 70 CBCTs.
The mean doses to target volumes were within the prescribed
range, displayed in Table 1. Except for one plan with 5 mm margins,
all plans had adequate PTV coverage of D98/95. In some cases,
PTVs had to be cropped 1 mm inside of the body surface: in the
5 mm plans in 7/10, in the 4 mm plans in 4/10 and in the 3 mm plans
in 2/10 dogs. Regarding the PTV D98%, the sign test showed differ-
ences: 4 mm-plans had higher D98% than the 5 mm-plans (P = 0.018),
with no differences between 5 mm-plans vs 3 mm plans (P = 0.050)
and the 4- and 3 mm-plans (P = 0.279). This observation reflects
insufficient build-up of the high dose-area in areas close to the body
surface or areas that were not covered sufficiently with bolus for
dose-build-up. Insufficient dose-build-up is corroborated by a
margin-independent lack of CTV-bool coverage (which was not
cropped inside the body surface), where in the 5- and 3 mm plans
6/10 patients had a D99% in 95% of volume coverage in all fractions,
and 7/10 patients in the 4 mm plan. The initially planned CTV cover-
age was lower than D99% in 95% of volume in 3/10 patients with all
PTV-margins. Due to surface cropping the PTV margins were smaller
than intended in some areas, resulting in underdosing CTVs close to
the body surface in bulging primary tumours.
3.3 | NTCP calculations of planned dataset vs
delivered treatment
The (relative) NTCP-values from the planned vs delivered or virtually
delivered doses generally showed systematic differences, an example
of which is shown in Figure 1A. The NTCP values as planned were
mostly lower than the values of the actually delivered doses.
For the different margins, the NTCPs of the delivered or virtu-
ally delivered doses were significantly different for all NTCP
parameter-value assumptions published, as summarized in Tables 2
and 3. The individual 2-level comparisons show that smaller margins
yield lower NTCPs (Figure 1B). The effect of smaller margins yielding
lower NTCPs was not seen for spinal cord delayed myelopathy. But
for spinal cord the overall risk was very low (<4%) and the spinal
cord was often sufficiently distant from the target. The risk of late
toxicity spinal cord necrosis was again significantly dependent on
margin size, albeit very low as well (<2%).
Given the lack of parameter data for the calculation of NTCP
values for the cauda equina, Dmean, Dmedian and Dmax for the delivered
and virtually delivered (4- and 3 mm-margin; mean of all fractions)
“radiation doses” to this OAR are presented in Table 4.
4 | DISCUSSION
The aim was to investigate if our currently used 5 mm PTV margin
provides appropriate dose coverage to the CTV for IG-IMRT in
treating tumours in the dog's abdominopelvic area, or if this margin
could even be reduced. While a lack in dose-coverage on the patient's
surface was identified in some cases, appropriate bolus-placement will
mitigate this loss of surface dose and ensure appropriate dose cover-
age for PTV extension margins as small as 3 mm, when delivered with
IG-IMRT. Doses to organs at risk were found to deviate slightly from
the predicted doses and normal tissue complication probabilities for
all organs but spinal cord myelopathy decreasing significantly for the
margin reductions.
TABLE 1 Mean volumes and delivered doses for target volumes
Mean Volume
(mean ± SD) [cm3]
D2%
(mean ± SD) [%]
D50%
(mean ± SD) [%]
D98%
(mean ± SD) [%]
D99%
(mean ± SD) [%]
Plan5mm: PTV_5mm 237.8 ± 94.6 104.0 ± 1.5 101.5 ± 1.1 92.8 ± 2.9
CTV_0_ plan5mm 116.6 ± 69.2
a 90.8 ± 11.5
CTVbool_plan5mm 124.7 ± 65.4
a 92.6 ± 9.9
Plan4mm: PTV_4mm 214.8 ± 88.5 103.3 ± 1.1 100.5 ± 0.6 95.5 ± 0.5
CTV_0_plan4mm 116.6 ± 69.2
a 92.5 ± 8.5
CTVbool_ plan4mm 124.7 ± 65.4
a 94.9 ± 5.3
Plan3mm: PTV_3mm 191.8 ± 82.7 103.1 ± 1.3 100.3 ± 0.4 95.4 ± 0.4
CTV_0_ plan3mm 116.6 ± 69.2
a 91.9 ± 8.8
CTVbool_ plan3mm 124.7 ± 65.4
a 94.0 ± 5.6
aThe volumes of the CTVs remain the same in all plans.
Abbreviations: CTV, clinical target volume; PTV, planning target volume.
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As described above, the effect of smaller margins yielding lower
NTCPs was not seen for spinal cord delayed myelopathy, most proba-
bly because the spinal cord was far away from the target and there-
fore the overall risk for spinal cord was very low (<4%). Another
explanation would be that during the patient positioning process, the
best match was performed in the region of the spinal cord as organ at
risk with most detrimental late toxicity - if it occurs.
In veterinary radiation therapy, margin guidelines often neither
exist nor can be extracted from older publications. Earlier treatments
were applied with simpler dose calculations (2D or 3D-CRT), without
daily online image guidance. For example, margins of 3 cm were used
in the postoperative setting (treated with Cobalt-teletherapy)22 or
2 cm margins surrounding CTV for a treatment planning study.23 In
the latter example, these large margins still yielded inaccurate treat-
ments, with non-graphic (two-dimensional) treatment plans found to
underdose CTVs between 0.6 and 50% (median 16%)!23 After evaluat-
ing daily online corrections with a rigid positioning device, we
described a smaller margin of 7 × 7 × 18mm for a correspondingly
positioned unguided approach and 3D-CRT treatment planning.15
A commonly accepted CTV-PTV expansion margin does not exist
for IG-IMRT radiation treatments in abdominopelvic tumours such as
anal sac, urinary bladder, prostate in dogs. The 5 mm was chosen as a
uniform CTV-PTV expansion to account for intra- and interfraction
variations in a series of genitourinary or anal sac tumours treated with
IG-IMRT.15,16 This margin can most likely be justified, as the online
correction of the pre-treatment CBCT eliminates the largest part of
the interfractional uncertainties (systematic errors). After correcting
for the systematic error with a couch shift, residual inaccuracy
resulting from respiratory movement, organ filling state and motion
influences the target's location. The dosimetric impact of this inaccu-
racy can be evaluated by checking the dose coverage in targets and
OAR at or even during the individual fractions. Adamson et al. (2010)
monitored prostate intrafractional motion in human prostate-cancer
patients treated with hypofractionated RT. By using kV fluoroscopy
during treatment, they found the probability of a 5 mm intrafraction
prostate displacement being very patient-specific and ranging from
0.0% to 58.8% of the time during a treatment session. The probability
of motion increased with treatment duration.24 In terms of target
dose coverage in these prostate patients, the investigators determined
right-left, anterior-posterior, and superior-inferior margins of 2, 3, and
4 mm to be sufficient to account for translational errors while limiting
the CTV D99% reduction to 1%.
25 Hence, in 29/30 of the prostate
tumour patients the reduction in CTV D99% was ≤5% when 3 mm uni-
form margins were used.25 In line with these findings, prostate-PTV
margins of ≥2 mm achieved the minimum dose coverage of 95% of
the prescription dose (based on mean, SD, and motion amplitudes)
even for patients with the largest motion.26 These findings are com-
mensurate with our results: a reduction to 4 mm or 3 mm PTV mar-
gins does not decrease CTV D99% to a relevant degree in most dogs
(Table 1). This is surprising as we used a boolean CTV - a worst-case
scenario approach. This approach, however, could lead to a marked
PTV extension in other parts of the body such as the thorax area
under respiratory movement. However, the result of similar CTVD99%
might be patient-specific and the planned PTV dose coverage could
F IGURE 1 Normal tissue complication probability (NTCP) values for early rectal radiation toxicity21 in all 10 dogs: A, Planned (filled symbols) vs
delivered or virtually delivered (in the 4- and 3 mm- margin plans) “radiation doses” for each patient, expressed by the NTCP as risk surrogate.
B, Example of lower NTCP from the plans with smaller PTV margins: original 5 mm margin (circles) vs 4 mm (squares) and 3 mm (triangles)
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not be reached in one patient with a very large, bulging primary
tumour close to the surface. In this and six other patients the PTVs
had to be cropped 1 mm inside the body outline for planning pur-
poses, resulting in a smaller margin in this area (and mostly remaining
insufficient dose-buildup). The surface dose loss is also reflected in
the increasing overall PTV dose coverage from the smaller 4 mm vs the
5 mm plan. In consequence, some patients (even with sufficient PTV
coverage in the planned version) had a margin-independent lack of
CTV-bool D99% coverage. The planned CTV_0 D99% coverage, however,
was lower than the delivered (CTV-bool D99%) dose to the CTV, show-
ing that the delivered dose can actually be higher than initially planned,
if patient's shift is away from underdosed surface. Here, the daily posi-
tion error was in favour of dose coverage and “corrected” for the physi-
cal loss of dose at the surface. Appropriate bolus-placement, however,
can very likely mitigate this loss of surface dose and ensure appropriate
CTV coverage for PTV extension margins of as small as 3 mm.
As found for doses to organs at risk in the treated dogs, a ran-
domized assessment of standard or reduced margins for human pros-
tate cancer resulted in significantly lower organ at risk dose (rectum
and urinary bladder) with smaller margins.27 Clinically however, the
improved rectal dosimetry did not translate into a statistically signifi-
cant benefit in acute or late toxicity. This may relate to the low level
of theoretical side effects in this trial, most comparable to the low risk
for severe acute or late toxicity predicted for the herein used proto-
col.15 Smaller margins can still be of interest, especially when increas-
ing the total dose or decreasing fraction number of the treatment in
the abdominopelvic region.
The position of the rectum at the time of the treatment-
planning CT scan is not fully representative of the position during
treatment because of patient motion, inter- or intrafraction varia-
tions in rectal filling, intestinal gas, and urinary bladder filling.28 In
human patients, the probability of motion (tumour and organs at
risk) increases with treatment duration.24 By treating animal patients
under general anaesthesia, we limit the movement during radiation
therapy to respiratory and physiological organ movement and filling
state. Mean intrafraction movement for prostate and urethra was
found to be small, at ≤0.14 and ≤ 0.22 mm, with maximum
intrafraction movements being ≤1.4 and ≤ 1.5 mm, respectively.12
Intrafraction movement of the canine prostate in enema and rectal
balloon prepared dogs could be limited to ≤2 mm 95% of the time in
any directions.12 Prostate gland motion, however, cannot directly be
interpolated for other abdominopelvic tumours: anal sac adenocarci-
nomas for example are less influenced by urinary bladder filling sta-
tus and less mobile. On the other hand, caudal-dorsal pelvic tumours
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could be more susceptible for pitch and roll deviations, which are
less likely to occur in the centrally located, often roundish prostate.
Due to their strong volume fluctuance, urinary bladder tumours can
be highly variable in position, and treatment with an adaptive strat-
egy is recommended.11,29
A strength of this study includes the assessment of margin
volumes, relative to former point, for example, isocentric shift
assessments.11-13,29 Our CTVbool, however, represents a worst-
case scenario: by “boolean-combining” the CTVs we assigned the
same weight to all shifts, even if a shift only took place once in
one direction during the whole treatment. In addition, pitch and
roll errors had to be incorporated, due to a lack of a six-
dimensional couch. Still, we have found 3 mm PTV expansion
margins to provide sufficient dose coverage in most of our cases,
given appropriate surface build-up. Surface dose-build up is
usually improved when treating with multi-directional treatment
field arrangements (as used in static or rotational IMRT and
tomotherapy). Simple and proactive bolus placement, however, is
still warranted in selected cases, as it supports physical dose-
build-up even in the modern era of radiation therapy. We agree
with several other authors, however, in cautioning against reduc-
ing PTV margins to less than 3 mm.30-33
We acknowledge the limitations of our findings: (a) The comparison
of NTCP is made with human tolerance data.21,34-38 This approach was
chosen under the premises of the lack of structured data of radiation
toxicity in canine rectal and spinal cord tissue. While one could argue
that the NTCP value assumptions cannot be extrapolated from human
to dog, NTCP values serve as relative values in this evaluation, rather
than absolute. (b) An additional inherent potential error in this type of
study occurs in the comparison of dose delivered to OAR contoured on
TABLE 3 Changes in NTCPs for different OARs, calculated along published parameter sets
Parameter sets
(Reference)
3 related setsa 2-level comparisonsb
NTCPdelivered 5 mm vs
4 mm vs 3 mm
NTCPdelivered
5 mm vs 4 mm
NTCPdelivered
5 mm vs 3 mm
NTCPdelivered
4 mm vs 3 mm
Acute rectal toxicity
any Rancati et al.
(2005)
P < .001 P < .05 P < .01 P < .01
≥ grade 2 RTOG Strigari et al.
(2009)
P < .001 P < .01 P < .01 P < .01
severe proctitis Burman et al.
(1991)
P < .001 P < .01 P < .01 P < .01
Late rectal toxicity




P < .001 P < .01 P < .01 P < .01




P = .003 P = .10 P < .01 P < .01




P < .001 P < .01 P < .01 P < .01
Late spinal cord toxicity
myelopathy Schultheiss et al.
(2008)
P = .407 n.s. n.s. n.s.
necrosis Burman et al.
(1991)
P = .025 n.s. P = .05 P < .05
Abbreviations: NTCP, normal tissue complication probability; OARs, organs at risk; RTOG, radiation therapy oncology group.
aFriedman, non-parametric test.
bWilcoxon test for paired numbers.
TABLE 4 Mean, median and maximum delivered and virtually delivered (4- and 3 mm-margin) radiation doses to the cauda equina
Dmean (mean ± SD) [Gy] Dmedian (mean ± SD) [Gy] Dmax (mean ± SD) [Gy]
Cauda equina Plan5mm: planned 20.7 ± 9.6 20.8 ± 10.7 31.0 ± 8.4
delivered (mean) 21.1 ± 9.6 21.4 ± 10.9 31.4 ± 8.0
Cauda equina Plan4mm: planned 20.8 ± 8.9 20.6 ± 10.1 31.7 ± 7.0
delivered (mean) 21.3 ± 8.8 21.5 ± 10.0 31.9 ± 6.9
Cauda equina Plan3mm: planned 19.2 ± 8.3 19.0 ± 9.4 30.3 ± 6.5
delivered (mean) 19.5 ± 8.1 19.6 ± 9.3 30.2 ± 6.5
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CBCT: as the soft tissue resolution is lower and artefact susceptibility
(gas) is higher on CBCT relative to the better quality of the diagnostic
CT used for planning, the derived doses could thereby be slightly
skewed. Moreover, no contrast agent was used for CBCTs. (c) Changes
in body contour were not considered. Marked weight loss during radia-
tion therapy associated with possible body contour changes was rare
according to a recent study.39 However, body contour changes are still
possible despite stable weight and can for example happen in the region
of movable skin folds in the inguinal and/or abdomen region according
to personal experience. If this is in the order of several centimetres and
happens to occur in the path of an incident radiation beam this could
indeed change radiation dose and distribution.
Any proposed CTV PTV expansion margin is institution depen-
dent. The margin can vary with the patient immobilization devices
used, the actual recumbency (and maybe even size) of the animal, type
and accuracy of the image-guidance (kV- vs MV-CBCT). Further, it
also depends on the experience of the staff with the imaging matching
process. In-depth knowledge of inherent uncertainties of an institu-
tion's own set-up and radiation techniques is therefore advised.
In conclusion, while PTV-margins depend on patient immobiliza-
tion and on the institution's treatment technique and accuracy, daily
CBCT-IG-IMRT allows treatment with very small margins in the dog's
abdominopelvic area. Routine image-guidance helps to ensure appro-
priate target dose coverage while minimizing normal tissue complica-
tion probability when treating with the smallest possible margins.
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